What the FDA labels say about taking them together
Aspirin and hydrocortisone
Hydrocortisone's FDA label (Solu-Cortef) of August 27, 2026 names aspirin in its drug interactions section; the aspirin label PlainMeds reads does not name hydrocortisone. The hydrocortisone label: “Concomitant use of NSAIDs and corticosteroids increases the risk of gastrointestinal adverse reactions. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. …”
Check it at the source: the aspirin FDA label on DailyMed (effective September 9, 2025); the hydrocortisone FDA label on DailyMed (effective August 19, 2026).
What does the aspirin label say about hydrocortisone?
Aspirin's label (effective September 9, 2025) does not name hydrocortisone in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Medique Products Aspirin), Unifirst First Aid Corporation, effective September 9, 2025 (SPL set 9b28fed0-a993-ca72-e053-2995a90ac7fd), via openFDA; the full label on DailyMed
What does the hydrocortisone label say about aspirin?
Solu-Cortef label (Pharmacia & Upjohn Company LLC, August 27, 2026), drug interactionsNonsteroidal anti-inflammatory drugs (NSAIDs): Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.
Alkindi Sprinkle label (Eton Pharmaceuticals, Inc., April 21, 2026), drug interactionsClinical Impact: Concomitant use of NSAIDs and corticosteroids increases the risk of gastrointestinal adverse reactions. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids; … Intervention: Monitor patients receiving ALKINDI SPRINKLE and concomitant NSAIDs. CYP3A4 Inhibitors: concomitant administration may require a decrease in the ALKINDI SPRINKLE dose. ( 7 ) CYP3A4 Inducers: concomitant administration may require an increase in the ALKINDI SPRINKLE dose. …
Source: FDA drug label (Solu-Cortef, NDA009866), Pharmacia & Upjohn Company LLC, effective August 27, 2026 (SPL set 65eefd58-b166-4d71-ade6-45c8fdf86922), via openFDA
Source: FDA drug label (Alkindi Sprinkle, NDA213876), Eton Pharmaceuticals, Inc., effective April 21, 2026 (SPL set 26c13a5f-7119-4c6a-bf10-fda4e07d7682), via openFDA
Source: FDA drug label (hydrocortisone 1), Kroger Company, effective August 19, 2026 (SPL set f05edff2-2dc5-427c-b52c-518e0aaef4e0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aspirin | Hydrocortisone | |
|---|---|---|
| Labeled for | Pain, Cough and cold, Fever | Osteoarthritis, Asthma, Allergies, Herpes and shingles, Leukemia, lymphoma and myeloma, Crohn's disease and ulcerative colitis, Eczema (atopic dermatitis) |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0142 per tablet 81 mg tablet | $0.0613 per gram 1% cream |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once